Minimization protocols in pancreas transplantation
- 1 January 2009
- journal article
- review article
- Published by Frontiers Media SA in Transplant International
- Vol. 22 (1) , 61-68
Abstract
Diagnosis of immunologic injury (acute and chronic) is much more difficult in pancreas transplants when compared with transplants of other organs. Currently, the immunosuppressive regimen for induction involves calcineurin inhibitors (CNI), antimetabolites and corticosteroids (Cs). This strong and nonspecific regimen does not take into consideration pancreas specificities (i.e. the need to avoid diabetogenic compounds). For obvious reasons, CNI might be calling for review, if permanently indicated in recipients of solitary pancreas with mild renal dysfunction. CNI as well as corticosteroids may induce hyperglycemia and contribute to differential diagnosis of a rejection process. However, in spite of the benefits accruing from withdrawal of above immunosuppressive agents, minimization or avoidance of these drugs could be dangerous and may end up with graft loss (i.e. antibody-mediated process). Long-term results of pancreas transplantation are now achieving comparable survival rates similar to the transplant of traditional organs such as kidney and liver. As a consequence, the physicians' objectives are to prolong the patient's quality of life and organ function as long as possible. Weaning strategies in regard to CNI and steroids are tested. Sirolimus, everolimus, CTLA-4 Ig, etc, are agents known to be either both nonnephrotoxic and nondiabetogenic or less so when compared with CNI. Their impact on pancreas transplantation is beginning to be evaluated. Large randomized trials in all pancreas categories, with long-term clinical and histologic results, are mandatory to establish new guidelines for immunosuppressive regimens for pancreas transplantation.Keywords
This publication has 29 references indexed in Scilit:
- Immunosuppression: Evolution in Practice and Trends, 1994–2004American Journal of Transplantation, 2006
- Pancreas transplant outcomes for United States (US) and non‐US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004Clinical Transplantation, 2005
- PROSPECTIVE, RANDOMIZED TRIAL OF THE EFFECT OF ANTIBODY INDUCTION IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION: THREE-YEAR RESULTS1Transplantation, 2004
- Immunosuppression: practice and trendsAmerican Journal of Transplantation, 2004
- Immunobiology, Diagnosis, and Treatment of Pancreas Graft Rejection2004
- Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study1Transplantation, 2003
- Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantationTransplant International, 2001
- MULTICENTER SURVEY OF DACLIZUMAB INDUCTION IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANT RECIPIENTS1, 2Transplantation, 2001
- Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: Evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainageSurgery, 2000
- Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantationKidney International, 1998